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Abstract
Background: The relationship between relative metabolic disturbances and developmental disorders is an
emerging research focus. This study compares the nutritional and metabolic status of children with autism with
that of neurotypical children and investigates the possible association of autism severity with biomarkers.
Method: Participants were children ages 5-16 years in Arizona with Autistic Spectrum Disorder (n = 55) compared with
non-sibling, neurotypical controls (n = 44) of similar age, gender and geographical distribution. Neither group had taken
any vitamin/mineral supplements in the two months prior to sample collection. Autism severity was assessed using the
Pervasive Development Disorder Behavior Inventory (PDD-BI), Autism Treatment Evaluation Checklist (ATEC), and Severity
of Autism Scale (SAS). Study measurements included: vitamins, biomarkers of vitamin status, minerals, plasma amino
acids, plasma glutathione, and biomarkers of oxidative stress, methylation, sulfation and energy production.
Results: Biomarkers of children with autism compared to those of controls using a t-test or Wilcoxon test found
the following statistically significant differences (p < 0.001): Low levels of biotin, plasma glutathione, RBC SAM,
plasma uridine, plasma ATP, RBC NADH, RBC NADPH, plasma sulfate (free and total), and plasma tryptophan; also
high levels of oxidative stress markers and plasma glutamate. Levels of biomarkers for the neurotypical controls
were in good agreement with accessed published reference ranges. In the Autism group, mean levels of vitamins,
minerals, and most amino acids commonly measured in clinical care were within published reference ranges.
A stepwise, multiple linear regression analysis demonstrated significant associations between several groups of
biomarkers with all three autism severity scales, including vitamins (adjusted R2 of 0.25-0.57), minerals (adj. R2 of
0.22-0.38), and plasma amino acids (adj. R2 of 0.22-0.39).
Conclusion: The autism group had many statistically significant differences in their nutritional and metabolic
status, including biomarkers indicative of vitamin insufficiency, increased oxidative stress, reduced capacity for
energy transport, sulfation and detoxification. Several of the biomarker groups were significantly associated with
variations in the severity of autism. These nutritional and metabolic differences are generally in agreement with
other published results and are likely amenable to nutritional supplementation. Research investigating treatment
and its relationship to the co-morbidities and etiology of autism is warranted.
Background and Significance
Vitamins, minerals, and essential amino acids are, by
definition, essential for human health, primarily due to
their critical function as enzymatic cofactors for numer-
ous reactions in the body, such as the production of
neurotransmitters and fatty acid metabolism Historically
attention has focused on inadequate intake of vitamins
and minerals due to poor diet as a major contributing
factor to many child health problems in the US and
around the world, including anemia (low iron),
hypothyroid (low iodine), scurvy (vitamin C deficiency),
and rickets (calcium and/or vitamin D deficiency). How-
ever, nutritional status depends not only on intake, but
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also on digestion, absorption, metabolic processing, and
metabolic demand. More recently the focus has shifted
to the relationship between relative metabolic distur-
bances and developmental disorders, for example those
associated with Attention Deficit Disorder [1-5], learn-
ing disorders [6], and intellectual development [7]. We
hypothesize that nutritional insufficiency and metabolic
imbalances may play a role in autism spectrum disor-
ders (ASD).
There have been several studies of the nutritional and
metabolic status of children with autism, but each
focused on study of only a few biomarkers. Three studies
have demonstrated that children with autism have
impaired methylation, decreased glutathione, and oxida-
tive stress [8-10], and those studies demonstrated that
nutritional supplementation (with vitamin methyl-B12,
folinic acid, and trimethylglycine) is beneficial. One study
in Romania found normal levels of vitamin B12 and
folate in children with autism compared to controls, but
low levels of plasma glutathione [11]. Several other stu-
dies have also demonstrated increased oxidative stress
[12-15]. One study [16] found that children with autism
had high levels of plasma vitamin B6 pre-supplementa-
tion, and this finding was confirmed in a follow-up study
[17], suggesting a metabolic imbalance in B6. One study
of dietary intake of 111 autistic children in China found
that most had inadequate intake of folic acid, vitamin B6,
vitamin A, Vitamin C, and zinc [18]. One study of vita-
min D status in Egypt found that young children with
autism had lower levels of vitamin D, both 25(OH)D and
1,25(OH)(2)D compared to age-matched controls [19].
One study in Slovakia found that children with autism
had significantly higher levels of vitamin C and beta-car-
otene, but normal levels of vitamin A and vitamin E,
compared to older teen controls [20].
There are several studies of minerals in children with
autism. One study found that young US children with
autism and their mothers had unusually low levels of
lithium compared to neurotypical children and their
mothers; lithium is receiving increasing recognition as
being an essential mineral [21]. Two large studies of
iron status found that US and Canadian children with
autism had anemia in 8% and 16% of cases, respec-
tively [22,23]. One small study of minerals in red
blood cells found that young Canadian children with
autism (n = 20) had lower levels of RBC selenium and
RBC molybdenum than neurotypical children (n = 15)
of the same age [24], but similar levels of most other
minerals. A small study of zinc and copper in plasma
found that British children with autism (n = 20) had
similar levels to neurotypical children (n = 30) [25]. In
contrast, a study of Turkish children with autism (n =
45) found that they had lower levels of zinc in plasma
and RBC compared to neurotypical children (n = 41)
[26]. One study [27] reported low levels of plasma zinc
and high levels of serum copper in young children
with autism as compared to published reference
ranges, but.the lack of in-study controls is a weakness
of this study.
There have been several studies of essential amino
acids in autism with conflicting results. Increased levels
were found by Aldred et al 2003 [28], both increased
and decreased levels by Moreno et al 1996 [29], and
decreased levels by Rolf et al 1993 [30] and Arnold et al
2003 [31]; the latter found only decreased methionine in
the autism group on a standard diet. One limitation of
the studies was their small population size (less than 25
participants in each arm). Another very important lim-
itation is that fasting status was unclear in two of the
studies [29,30] or only involved a limited (2-4 hours)
fast in another study [31]. Only one of the studies [28]
involved overnight fasting; this is important as amino
acid values are not comparable unless all are done in a
fasting state. One of the studies [28] involved very dif-
ferent age ranges for the controls and the autistic group
which is important as pediatric reference ranges for
some plasma amino acids vary substantially with age
[32]. Thus, larger, more rigorous studies are needed.
The purpose of this study is to investigate the nutri-
tional and metabolic status of children with autism
compared to neurotypical children of similar age and
gender, and to determine if some nutritional and meta-
bolic biomarkers may be associated with the severity of
autism. This study includes a broad array of biomarkers
because that helps provide a more complete understand-
ing of nutritional status, including vitamins, minerals,
amino acids, and other metabolic biomarkers. The chil-
dren with autism who participated in this study then
continued into a randomized, double-blind, placebo-
controlled study of the effect of a vitamin/mineral sup-
plement, and the details of that follow-on investigation
are reported in two companion papers [Adams et al,
Effect of a Vitamin/Mineral Supplement on Children
with Autism: Part A Nutritional and Metabolic Results,
submitted, and Adams et al, Effect of a Vitamin/Mineral
Supplement on Children with Autism: Part B. Effect on
Symptoms.]. A strength of this study is the use of neu-
rotypical controls of similar age, gender and geographic
distribution, tested concurrently under identical condi-
tions to the autism group, with blinded evaluation of
samples by the laboratories.
Methodology
This paper reports on the baseline levels of children
with autism compared to neurotypical children. Neither
group of children had taken any vitamin/mineral supple-
ments in the two months prior to the study. This study
was conducted with the approval of the Human Subjects
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Institutional Review Board of Arizona State University,
study protocol number 0801002499.
Participants
Participants were recruited during May to December
2008 from Arizona with the help of the Autism Society
of Greater Phoenix and the Arizona Division of Devel-
opmental Disabilities. All parents and children, where
appropriate for age and developmental ability, signed
parent consent/child assent forms.
Enrollment criteria
1) age 5-16 years old;
2) no usage of a vitamin/mineral supplement in the
last 2 months
3) no current use of any chelation treatment
4) Autism Group: prior diagnosis of autism, PDD/
NOS, or Asperger’s by a psychiatrist or similar profes-
sional, with written verification (no additional assess-
ment was done in this study)
5) Control Group: in good mental and physical health,
and no siblings with autism spectrum disorders, and no
evidence of Attention Deficit Disorder by parent report
(no additional assessment was done in this study)
Participants
The characteristics of the study participants are listed in
Table 1, and their physical and behavioral symptoms
(per the ATEC) are listed in Table 2.
Study Protocol
1) Participant parents contacted the study coordinator,
and the study was explained by telephone. Consent/
assent forms were sent to the parents for review, and
then signed copies were brought to the study coordina-
tor. The Principal Investigator (J.B. Adams) also dis-
cussed the study personally with each participant.
2) Parents of children with autism completed three
questionnaires relating to the severity and symptoms of
autism (see below).
3) The study physician conducted a physical exam to
determine that the children were in adequate health for
participating in the study.
4) Morning blood samples (50 ml) were collected after
an overnight fast (8-12 hours). Morning urine samples
were collected, and in almost all cases these were first-
morning (overnight) urines.
5) All study data (questionnaires and laboratory sam-
ples) were assigned a coordinating subject code. All
laboratory analyses were done blinded to subject group
(Autism or Control).
Lab Measurements
Minerals and plasma amino acids were measured by
Doctor’s Data (St. Charles, IL, USA - http://www.doc-
torsdata.com). Vitamins, serum ferritin, and all other
biomarkers were measured by Vitamin Diagnostics
(South Amboy, NJ, USA; http://www.europeanlabora-
tory.nl). Both laboratories are certified by CLIA, the
Clinical Laboratory Improvement Amendments program
operated by the US Department of Health and Human
Services which oversees approximately 200,000 labora-
tories in the US.
Measurement methods are summarized in Table 3.
For urine analyses, correction for variations in dilution
was done by adjusting for specific gravity [33] or by nor-
malizing to grams of creatinine.
Vitamins were measured in the blood compartment
(serum, plasma, or RBC) where they are most highly
concentrated, or if evenly distributed intra- and extra-
cellularly then whole blood was measured. Fat-soluble
vitamins (A, D, E, K) are primarily concentrated in
serum. For water-soluble vitamins, some are primarily in
the plasma (like vitamin C), whereas others (like pan-
tothenic acid) are significantly present in both serum
and RBC, so whole blood was used. This approach then
provides the best estimation of total body levels. Whole
Table 1 Characteristics of Participants
Autism Group Neurotypical Group
Total
Participants
55 44
Male 49 (89%) 39 (89%)
Female 6 (11%) 5(11%)
Age (years) 10.0 +/- 3.1 11.0 +/- 3.1
Diagnosis 85% autism, 4% PDD/
NOS, 11% Asperger’s
In good mental and
physical health
Medications 55% no medications
29% psycho-
pharmaceuticals -
primarily risperidone and
clonidine;
9% on CNS stimulants
(primarily Concerta); 4%
on anti-convulsants
5% on GI medications;
7% on asthma/allergy
medicine;
2% on insulin
89% no medications;
9% on anti-inflammatories
(asthma/allergies); 2% on
anti-incontinence
medication
Special Diets 84% on regular diet;
3 gluten-free, casein-free
diet;
1 gluten-free;
3 reduced dairy/gluten;
2 low sugar
1 child on dairy-free diet
Nutritional
Supplements
1 on fish oil; 2 on
melatonin
none
PDD-BI
(modified
autism
composite)
-63 +/- 54 n/a
ATEC 64 +/- 25 n/a
SAS 4.9 +/- 2.4 n/a
Adams et al. Nutrition & Metabolism 2011, 8:34
http://www.nutritionandmetabolism.com/content/8/1/34
Page 3 of 32
blood measurements are not commonly used for labora-
tory assessments because of challenges in processing the
samples. However, by the use of vitamin-specific micro-
biological organisms as done in this study, whole blood
levels are measured with a high degree of reliability.
Essential minerals were measured in RBC, serum,
whole blood, and (for iodine) in urine. In most cases,
serum reflects an average of the last several days, RBC
reflects an average of the last several months, and
whole blood is an average of both. Serum Na, K, Mg,
Ca, P, Fe were analyzed on an automated clinical chem-
istry analyzer (Olympus AU680, Olympus America Inc.;
Centerville, Pa., USA) using commercial assays. Essential
minerals were measured in RBC in all cases except for
sodium, lithium, and iodine; most were also measured
in whole blood and/or serum depending upon which
compartment is known to have the higher concentration
for that mineral. Lithium was only measured in whole
blood because it is more detectable there. Iodine was
measured in urine (see below) because it is more
detectable and reliably measured in urine than in blood.
Whole blood and packed red blood cells were collected
in a potassium EDTA trace metal free (royal blue top;
BD Vacutainer, Franklin Lakes, NJ). Packed red blood
cells were spun for 15 minutes in a centrifuge at 1500 g
(g-force), the plasma and buffy coat were removed and
the remaining packed red blood cells were submitted
for testing. Elemental analysis was performed after
digesting an aliquot of sample using a temperature con-
trolled microwave digestion system1 (Mars5; CEM Corp;
Matthews, SC), following the same procedure for nitric
acid microwave digestion and sample procedure as used
previously for hair [34]. The digested sample was ana-
lyzed by Inductively Coupled Plasma - Mass Spectrome-
try (ICP-MS) (Elan DRCII; Perkin Elmer Corp; Shelton,
CT). Results were verified for precision and accuracy
using controls from Doctor’s Data and Seronorm whole
blood controls (Sero; Billingstad, Norway).
Urine iodine was analyzed by ICP-MS using a modifi-
cation of the methods reported in the Analytical section
of the report by the Agency for Toxic Substances and
Disease Registry (ATSDR 2004). Urine results are
expressed per gram creatinine.
Amino Acids After an overnight fast blood samples
were collected into purple top (EDTA) tubes. Blood
was centrifuged within 30 minutes, and plasma was
mixed with 5-sulfosalicylic acid to precipitate proteins
prior to freezing for 24 hours prior to shipping. Plasma
amino acids were analyzed by a reversed phase high
performance liquid chromatography (HPLC) tandem
mass spectrometry (MS/MS) technique (Prostar 420
HPLC autosampler, Prostar 210 solvent delivery mod-
ule, 1200 L mass spectrophotometer, Varian, Inc.; Palo
Alto, CA) using a method developed at Doctor’s Data.
Results were verified for precision and accuracy using
in-house controls and a Native (Physiological) Sample
Standard (Pickering Laboratories). Note that the mea-
surement process results in oxidation of any cysteine,
so that the measurement of “cysteine + cystine” is
actually a measure of the combination of cysteine and
cystine. The same is true of homocysteine and
homocystine.
Assessing Autistic Symptoms and Severity
Three tools were used to assess the severity and symp-
toms of autism, namely the Pervasive Development Dis-
order Behavior Inventory (PDD-BI) [35], Autism
Evaluation Treatment Checklist (ATEC) [36] and Sever-
ity of Autism Scale (SAS) [37]. For the PDD-BI, a modi-
fied Autism Composite was used, following the example
of a previous study [37]. That is, the Semantic/Prag-
matic Problems (SemPP) subscale was omitted as
Table 2 Symptoms of Autism Participants, per the ATEC
Subscale on Health/Physical Behavior
Symptom % with moderate or severe
problem
bedwetting 20%
wets pants/diapers 16%
soils pants/diapers 20%
diarrhea 18%
constipation 41%
sleep problems 40%
eats too much/little 68%
limited diet 53%
hyperactive 40%
lethargic 17%
hits/injures self 18%
hits/injures others 24%
destructive 24%
sound sensitive 44%
anxious/fearful 27%
unhappy/crying 14%
seizures 4%
obsessive speech 33%
rigid routines 35%
shouts/screams 50%
demands sameness 43%
often agitated 41%
not sensitive to pain 30%
hooked or fixated on certain
objects
63%
repetitive movements 38%
This section was rated on a scale of 0 (none), 1 (mild), 2 (moderate), 3
(severe). Below are listed the percentages with moderate or severe problems,
as reported by parents.
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children with no spoken language inappropriately score
as less severe than those with limited language. The
resulting modified Autism Composite consisted of Sen-
sory/Perceptual Approach, Ritualisms/Resistance to
Change, Social Pragmatic Problems, Social Approach
Behaviors, Phonological and Semantic Pragmatic
subscales.
Statistical Analysis
Several types of statistical analyses were used, depending
on the research question being addressed. In comparing
levels between groups (such as children with autism vs.
neurotypical children), 2-sided unpaired t-tests were
used. The unpaired t-tests were either done assuming
equal variance or unequal variance, based on the results
Table 3 Analytical methods for some of the measurements
Analyte Source Methodology
Vitamin A Plasma Spectrophotometry [80]
Total Carotenes (alpha, beta, epsilon,
gamma)
Plasma Spectrophotometry [81]
Vitamin C (sum of reduced and oxidized
forms)
Plasma Spectrophotometry [82]
Vitamin D3 (25-hydroxy) plasma Measured in plasma by liquid chromatography - tandem mass spectroscopy (LC/MS/MS) [83]
Vitamin E (total tocopherols, including
alpha, gamma1, gamma2)
serum Spectrophotometry [84]
Vitamin K plasma Vitamin K was extracted from plasma by methylene chloride in a monophasic design, purified
on a C-18 cartridge, separated on a reversed-phase column, and then detected fluorometrically
[85]
Thiamine Whole
Blood
Microbiological Assay [86]
Riboflavin Whole
Blood
Microbiological Assay [87]
Niacin Whole
Blood
Microbiological Assay [88]
Pantothenic Acid Whole
Blood
Microbiological Assay [89]
P5P RBC Microbiological Assay [90]
Biotin Whole
Blood
Microbiological Assay [91]
Folic Acid Serum Microbiological Assay [92]
Vitamin B12 Plasma Microbiological Assay [93]
Choline (Free and Total) RBC Microbiological Assay [94]
Alpha lipoic acid Plasma Microbiological Assay [95]
CoQ10 Plasma Reverse-phase high-performance liquid chromatography (HPLC) using hexane extraction on a
C-18 column (15 cm, 5 micron) with methanol:hexane (95:5) as the mobile phase and UV
detection [96]
Adenosine, Inosine, Uridine Plasma HPLC with 254 adsorption [97]
Formimino-glutaric acid (FIGLU) Urine Spectrophotometrically [98] after adjustment of specific gravity at neutral pH [99]
Kryptopyrole Urine Spectrophotometrically [100] after adjustment of specific gravity at neutral pH [99]
Methylmalonic Acid Urine Liquid chromatography - tandem mass spectroscopy (LC-MS/MS) with electrospray ionization
[101], expressed per gram creatinine
N-methylnicotinamide Urine HPLC, with ultraviolet diode array detection [102], and the results are expressed per gram
creatinine
Serum Ferritin Serum Immunometric assay with Immunlite 2000 (Diagnostics Product Corp., Los Angeles, California)
S-adenosylmethionine (SAM) and S-
adenyosylhomocysteine (SAH)
RBC Extracted from RBC [103] and measured by LCMS [104]
Glutathione (GSH and GSSG) Plasma Fluorescence detector [105]
Nitrotyrosine Plasma LCMS [106]
ATP Plasma Luciferin-luciferase assay [107]
NADH, NADPH RBC Spectrophotometry [108]
Sulfate (Free and Total) Plasma Using indirect atomic absorption spectrometry [109]
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of a test for equal variance. For individual comparisons a
p value of 0.05 or lower was assumed significant. How-
ever, in order to maintain an overall significance of 5%
when multiple comparisons were considered, a smaller
per-test p-value was considered significant based on a
Bonferroni analysis, and this p-value is specified at the
beginning of each of the result sections. For example, if
making 5 comparisons, then an overall significance of
5% is achieved if the p-value is set at 0.05/(5 compari-
sons) = 0.01. We use the term “marginally significant” if
the p value is less than 0.1/(number of comparisons).
We use the term “possibly significant” if the p-value is
less than 0.05 but not low enough to be marginally sig-
nificant; this means that the result would be significant
if only one comparison were made, but could be a sta-
tistical fluke due to the making of many comparisons,
so further studies are needed to confirm or invalidate
the result.
Some of the data for essential minerals were not nor-
mally distributed, so in those cases a non-parametric
Wilcoxon test was used instead of a t-test. Pearson cor-
relation coefficients were obtained to determine the
strengths of linear relationships among the variables
involved in the analyses.
Note that for a few measurements there was some
data below the detection limit. In those cases the value
of the detection limit was substituted for the data point;
so, for cases where some samples were below detection
limit, our reported measured values are an upper bound
to the true value.
Correlation and regression analysis was employed to
examine the relationship between the severity of autism
(assessed by the ATEC, PDD-BI, and SAS) and the bio-
markers of nutritional and metabolic status. For the
selected dependent and independent variables, step-wise
linear regression analyses were conducted: initially all
independent variables were included in the regression;
then at each step, the variable with the highest p-value
was eliminated, and this process was continued until the
adjusted R2 value began declining. Thus, the goal was to
determine the best fit to the sample data for the selected
model, taking into account the correlation among the
independent variables. Since the data had several miss-
ing values (due to missing lab or behavioral data), the
regression analyses were conducted by restricting the
analysis to “complete cases” only (i.e., where there were
no missing values for any of the variables in the initial
analysis step). Due to the large number of biomarkers
compared to the number of participants, the regression
analyses were first conducted by category; for example,
vitamins vs. the PDD-BI as the dependent variable.
After determining, for each category, the few within-
category biomarkers that had the greatest association
with autism severity, an “overall” step-wise regression
was performed on those biomarkers with the greatest
association with autism severity. Since that “overall”
analysis involved a large number of variables compared
to the number of participants, the overall analysis needs
to be interpreted cautiously.
Results
Correlation Of Autism Severity Scales
As shown in Table 4, the PDD-BI, ATEC, and SAS
scales were strongly correlated with one another, R =
0.75-0.81, similar to the findings of a previous study
[37].
Comparison of Neurotypical and Autism Groups with
Published Reference Ranges
Reference ranges for the neurotypical children in this
study were calculated based on the 10th and 90th per-
centiles of their distribution. This is more exact than
using +/- two standard deviations if the data is not nor-
mally distributed, which sometimes was the case. These
calculated reference ranges were compared with pub-
lished reference ranges for vitamins (Table 5), minerals
(Table 6), primary amino acids, and secondary amino
acids. Two primary sources were used for vitamins and
minerals: 1) the National Health and Nutrition Examina-
tion Survey (NHANES) National Report on Biochemical
Indicators of Diet and Nutrition in the US Population
1999-2002 [38], and 2) the Tietz Textbook of Clinical
Chemistry [39]; both are generally viewed as highly
credible sources for the US population. In some cases
only adult reference ranges are available from those
sources. Despite the differences in techniques and meth-
odologies, the agreement with the NHANES reference
ranges is very good, and the agreement with the Tietz
reference ranges is reasonable, especially when compar-
ing to pediatric values. The agreement with published
reference ranges is a validation of our methodology and
of our calculated reference range for neurotypical chil-
dren, which we will compare with the autism group in
the next section. The advantage of having our own
reference range for neurotypical children is that it clo-
sely matches the age, gender, and geographical area
(Arizona) of our autism group.
The amino acid reference ranges (10th and 90th per-
centiles) for the neurotypical group (present study) were
Table 4 Correlations of autism severity scales
Modified PDD-BI-
Autism
ATEC SAS
Modified PDD-BI-Autism
Composite
1
ATEC 0.81 1
SAS 0.78 0.75 1
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Table 5 Vitamins: The average levels of vitamins measured in the Autism and Neurotypical groups are reported below, along with their standard deviations
Vitamins Units Autism
Group
Neuro-
typical
Group
%
Difference
p-value Neurotypical Reference
Range (10th and 90th
percentiles)
Autism
Group %
below RR
Autism
Group %
above RR
Tietz
Reference
Range [39]
NHANES1999-2002
Reference Range (6-11 yr
and 12-19 yr) [38]
Sonora
Quest
Vit. A (plasma) μg/100
ml
54.3
+/- 10.7
54.9
+/- 12
n.s. 39-71 0% 9% 26-61
(7-19 yr)
26.0-51.2
30.8-70.6
(in serum)
26-49
(7-12 yr,
in
serum)
Total Carotenes
(beta carotene and
other carotenes, in
plasma)
μg/100
ml
150
+/- 55
178
+/-53
-16% 0.01 111-251 29% 8%
Vit B1
Thiamine
(WB)
μg/l 64
+/- 10
63
+/-9
n.s. 48-72 11% 20% 56 +/- 12
(children
and young
adults)a
87-280
nmol.L
(adult)
Vit B2
Riboflavin
(WB)
μg/l 284
+/- 42
282
+/-52
n.s. 224-332 4% 15%
Vit B3
Niacin and
Niacinamide
(WB)
μg/l 7.00
+/- 1.1
7.07
+/-0.97
n.s. 5.9-8.2 16% 15%
Vit B5
Pantothenic Acid
(WB)
μg/l 640
+/- 128
714
+/-180
-11% 0.02 504-965 11% 0% 200-1800
(adult)
Vit B6 (as P5P in
RBC)
μg/l 17.9
+/- 16
15.2
+/-5.3
n.s. 8-21 13% 20%
Folic Acid (serum) μg/l 17.7
+/- 7.2
18.7
+/-6.1
n.s. 12-28 20% 7% 3-20
(adult)
9.9-33.2
6.0-24.7
3.1-17.5
(adult)
Vit B12
(plasma)
ng/l 699
+/- 235
676
+/-215
n.s. 327-938 4% 18% 200-835
(adult)
369-1260
267-941
(in serum)
243-394
(adult,
in
serum)
Vit C
(plasma)
mg/100
ml
1.57
+/- 0.61
1.33
+/-0.46
+18% 0.03 0.75-1.85 13% 29% 0.4-1.5
(adult)
0.2-1.7
(12-19 yr, in serum)b
0.2-1.9
(adult)
Vit D3
(25-hydroxy in
plasma)
μg/l 29.9
+/-8.4
28.6
+/-8.4
n.s. 19-44 9% 7% 14-60
(adult)
17-35
13-35
30-100
Total Vit E (serum) mg/100
ml
0.78
+/- 0.18
0.90
+/-0.32
-14% 0.03 0.6-1.4 9% 0% 0.45-0.95
(1-19 yr)
0.55-1.13
0.53-1.14
Biotin (WB) ng/l 394
+/-100
491
+/-164
-20% 0.001 * 257-709 7% 0% 200-500
(adult)
Vit K (plasma) ng/l 294
+/- 158
295
+/- 189
n.s. 129-530 9% 7% 130-1190
(adult)
80-1160
(adult)
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Table 5 Vitamins: The average levels of vitamins measured in the Autism and Neurotypical groups are reported below, along with their standard deviations
(Continued)
Vitamin-like
substances
Free Choline
(RBC)
mg/l 6.3
+/- 2.9
5.6
+/- 1.7
n.s. 4.0-7.6 22% 35%
Total Choline
(RBC)
mg/l 363
+/- 66
310
+/- 51
+17% < 0.0001 * 260-362 5% 53%
Lipoic Acid
(plasma)
μg/l 2.56
+/- 1.5
2.85
+/- 1.2
n.s. 1.2-4.5 5% 16%
Biomarkers of
functional need for
vitamins
FIGLU μg/l 1.99
+/- 0.92
1.62
+/- 0.72
+23 % 0.03 0.65-2.6 5% 27%
Methylmalonic Acid mg/g-
creatinine
9.0
+/- 7.3
7.5
+/- 5.0
n.s. 1.6-13.7 2% 13%
N-methyl-
nicotinamide
mg/g-
creatinine
5.0
+/- 4.4
3.6
+/- 2.3
+40% 0.04 1.2-7.1 13% 17%
Kryptopyroles μg/dl 39.3
+/- 30.
35.8
+/- 15
n.s. 14-56 13% 11%
The p-value for a t-test comparison of the two groups is also reported. If the p-value is below 0.05, then the % difference between the groups is reported, and the result is highlighted.
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical,
10% would be above and 10% would be below. Percentages above 25% are highlighted. Reference Ranges from Tietz Textbook of Clinical Chemistry (Burtis and Ashwood 1999), the NHANES National Report, and
Sonora Quest are given where available.
a) From Wyatt et al 1991 [110].
b) From Schleicher et al 2009 [111], based on NHANES data from 1999-2002 [38].
* Statistically significant difference between the two groups with 95% confidence per Bonferroni analysis.
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Table 6 Essential Minerals and non-essential minerals measured in whole blood, RBC, serum, and urine
Essential Minerals +
other minerals
Units Autism
Group
Neuro-
typical
Group
%
Difference
p-value Neurotypical Reference
Range (10th and 90th
percentiles)
Autism
Group %
below RR
Autism
Group %
above RR
Tietz Ref.
Range
[39]
NHANES1999-2002
Reference Range (6-11 yr
and 12-19 yr) [38]
Sonora
Quest Ref.
Range
Calcium-WB mg/dl 5.9
+/- 0.4
5.8
+/- 0.3
n.s. 5.45-6.20 11% 11%
Calcium-RBC μg/g 19.3
+/-7
22.4
+/- 6
-14% 0.02 12.5-29.5 31% 7%
Calcium-Serum (total) mg/dl 9.6
+/- 0.5
9.6
+/- 0.2
n.s. 9.25-9.9 13% 9% 8.8-10.8
(2-12 yr)
8.8-10.8
(2-12 yr)
Chromium-RBC ng/g 0.91
+/-0.5
0.80
+/- 0.4
n.s. 0.3-14 9% 16%
Copper-WB μg/dL 95
+/-11
89
+/- 14
+7% 0.02 70-108.5 0% 11%
Copper-RBC μg/g 0.76
+/-0.08
0.72
+/- 0.09
+5% 0.03 0.61-0.86 2% 13%
Iodine-Urine μg/mg-
creatinine
0.24
+/- 0.2
0.26
+/- 0.3
n.s. 0.097-0.57 25% 4% 0.116-0.699
0.067-0.364
Iron-RBC μg/g 891
+/-94
833
+/- 64
+7% 0.0005 * 764-922 2% 42%
Iron-Serum μg/dl 83
+/- 34
87
+/- 35
n.s. 42-130 7% 7% 50-120
(child)
39-126
45-141
28-136
(6-14 yr)
Serum Ferritin μg/l 39.1
+/- 22
36.9
+/- 17
n.s. 17-63 9% 16% 7-140
(1 - 15 yr)
11-74
8.0-115
Lithium-WB μg/L 1.7
+/-0.8
3.6
+/- 6
-52% 0.006 W 1-5.0 11% 0%
Lithium-WB (without 3
highest neurotypical
outliers #)
μg/L 2.2
+/- 1.1
-23% 0.006 W 3.25-3.90 13% 7%
Magnesium-WB mg/dl 3.53
+/-0.31
3.64
+/- 0.26
-3% 0.02 W 42-54.5 18% 22%
Magnesium-RBC μg/g 48.9
+/-6
47.5
+/- 5
n.s. 1.8-2.2 4% 2% 40-64
(adult)
Magnesium-Serum mg/dl 1.95
+/- 0.14
2.03
+/- 0.15
-4% 0.02 W 8-16 13% 15% 1.7-2.1
(6-12 yr)
1.7-2.4
(adult)
Manganese-WB μg/L 12.1
+/4
11.6
+/- 3
n.s. 0.012-0.025 11% 20% 7.7-12.1
(adult)
Manganese-RBC μg/g 0.021
+/-0.007
0.018
+/- 0.005
+12% 0.07 W 1-1.8 6% 7%
Molybdenum-WB μg/L 1.4
+/-0.4
1.4
+/- 0.3
n.s. 0.15-0.30 7% 13% 0.8-3.3
(adult)
Molybdenum-RBC ng/g 0.93
+/- 0.3
0.98
+/- 0.2
n.s. 520-629 7% 33%
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Table 6 Essential Minerals and non-essential minerals measured in whole blood, RBC, serum, and urine (Continued)
Phosphorus-RBC μg/g 597
+/-59
567
+/- 43
+5% 0.004 3.85-5.35 6% 6%
Phosphorus-Serum mg/dL 4.6
+/- 0.5
4.6
+/- 0.5
n.s. 73-83.5 9% 20% 4.5-5.5
(2-12 yr)
3.1-5.9
(4-12 yr)
Potassium -RBC mEq/L 79
+/- 5.3
76.9
+/- 4.1
+3% 0.007 W 3.8-4.6 15% 9%
Potassium-Serum mEq/L 4.1
+/- 0.3
4.2
+/- 0.3
n.s. 186-236 19% 9% 3.4-4.7
(child)
2.8-6.0
(child)
Selenium-WB μg/L 207
+/-28
210
+/- 20
n.s. 0.20-0.27 9% 18% 58-234
(adult)
Selenium-RBC μg/g 0.24
+/- 0.04
0.23
+/- 0.03
n.s. 136-139 9% 17% 0.07-0.24
(adult)
Sodium-Serum mEq/l 138
+/- 2
137
+/- 1
n.s. 0.15-0.30 11% 2% 138-145
(child)
135-145
(adult)
Vanadium-RBC ng/g 0.21
+/- 0.07
0.22 +/-
0.07
n.s. 465-657 7% 7%
Zinc-WB μg/dL 551
+/-68
555
+/- 74
n.s. 6.8-10.8 2% 15%
Zinc-RBC μg/g 9.2
+/-1.4
8.9
+/- 1.4
n.s.
Non-essential minerals
Boron-RBC μg/g 0.029
+/-0.014
0.025
+/- 0.007
+16% 0.04 0.014-0.032 13% 36%
Strontium-WB μg/L 25
+/-8
24
+/- 6
n.s 17-34 7% 6%
The average levels of minerals measured in the Autism and Neurotypical groups are reported below, along with their standard deviations. The p-value for a t-test comparison of the two groups is also reported. If
the p-value is below 0.05, then the % difference between the groups is reported. For several tests the data was not normally distributed, and in those cases a non-parametric Wilcoxon test (also known as the Mann-
Whitney test) was used instead of a t-test - those p-values are marked with a W.
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical,
10% would be above and 10% would be below. Percentages above 25% are highlighted. Reference Ranges from Tietz Textbook of Clinical Chemistry (Burtis and Ashwood 1999), the NHANES National Report, and
Sonora Quest are given where available.
# Note that the lithium level for the neurotypical group is greatly increased by three siblings with very high lithium levels of 16, 16, and 35 mcg/L. A second value for lithium is given for the neurotypical group
without those 3 siblings; the difference between the autism group and this revised neurotypical group is smaller but slightly more significant.
* Statistically significant difference between the two groups with 95% confidence per Bonferroni analysis.
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compared with pediatric reference ranges by Lepage et
al [33] and (where available) with values from the Tietz
Textbook of Clinical Chemistry [39]. For Lepage et al
[33], two reference ranges are listed, one for 6 year olds
and one for 16 year olds. In most cases the values from
the present study are in reasonable agreement with the
published values.
For the autism group, the average (mean) levels of
their vitamins, minerals, and most amino acids were
within the published reference ranges (where available).
However, as will be discussed below, a t-test comparison
of the levels of vitamins, minerals, amino acids, and
other biomarkers in the autism group and the neuroty-
pical group revealed many significant differences.
Comparisons of biomarkers between autistic and
neurotypical groups
Vitamins
Table 5 shows the participants’ levels of vitamins, vita-
min-like substances, and biomarkers of vitamin status.
Because we are making multiple comparisons (our
hypothesis is “are the levels of any vitamins different in
children with autism vs. controls”), we need to apply a
Bonferroni correction (see statistical analysis section).
For 21 comparisons, p values are defined as: “significant”
= p < 0.002, “marginally significant” = p < 0.005, and
“possibly significant” = p < 0.05. Figure 1 compares the
levels of vitamin-related biomarkers that were different
in the autism group compared to the control group.
For the vitamins, the only significant difference was a
20% lower biotin (p < 0.001) in the children with autism.
There were possibly significant (p < 0.05) lower levels of
vitamin B5, vitamin E, and total carotenoids. Vitamin C
was possibly slightly higher in the children with autism.
Vitamin B6 (measured as the active form, P5P, in the
RBC) had an unusually broad distribution in children
with autism compared to controls (see Figure 1), with the
levels in the children with autism having 3 times the
standard deviation of the neurotypical children.
The levels of two vitamin-like substances, lipoic acid
and choline (free and total) were also assessed. Levels of
lipoic acid and free choline were similar in the two
groups, but total choline was 17% higher in the autistic
group (p < 0.0001).
The functional need for vitamins was indirectly
assessed by measurements of several urinary metabo-
lites, including FIGLU, kryptopyroles, methylmalonic
acid, and n-methyl-nicotinamide. FIGLU and n-methyl-
nicotinamide were somewhat higher in children with
autism (possibly significant, p < 0.05), suggesting an
increased need for folic acid and niacin, respectively.
The average levels of urinary kryptopyroles were not sig-
nificantly different in children with autism, but the chil-
dren with autism had a much broader distribution.
For most vitamins, children with autism have levels
that lie within the neurotypical reference ranges
defined by the 10th and 90th percentiles (see Table 5).
However, there are some cases where more than 25%
of the autism group lie below the neurotypical refer-
ence range (total carotenes) or above the neurotypical
reference range (vitamin C, free choline, total choline,
FIGLU).
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Figure 1 Vitamins and related substances which were significantly different between the autism and neurotypical groups, rescaled to
the average neurotypical values. The average values and the standard deviations are shown. The number of asterisks indicates the p-value (*
p < 0.05, ** p < 0.01, *** p < 0.001).
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Essential Minerals
Table 6 shows the levels of minerals in whole blood
(WB), red blood cell (RBC), serum, and urine (for
iodine) for the study participants. (28 comparisons:
“significant” is p < 0.002, “marginally significant” is p <
0.004, and “possibly significant” is p < 0.05). Figure 2
shows the levels of minerals which were different
between the autism and neurotypical groups.
The largest difference was a much lower level of WB
lithium (-53%, p < 0.006). Note that three of the con-
trols had unusually high levels of WB lithium, and were
from the same family, so the data is analyzed with and
without their data; removing their results reduces the
magnitude of the difference, but the significance of the
result remains the same.
Iron status was measured in three ways: serum ferri-
tin, serum iron, and RBC iron. The first two did not
reveal any difference between the two groups, but RBC
iron was slightly higher in the children with autism
(+7%, p < 0.0005), with 42% of the children with autism
having levels above the 90th percentile for the typical
children.
There were small, possibly significant differences in
several other minerals. There were possibly significant
slightly higher levels of RBC potassium, RBC phos-
phorus, copper (WB and RBC), and RBC boron, and a
possibly significant lower level of RBC calcium and mag-
nesium (serum and WB).
For most minerals, children with autism have levels
that generally lie within the neurotypical reference
ranges (see Table 6). However, there are some cases
where more than 25% of the autism group lie below the
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Figure 2 Minerals which were significantly different between the autism and neurotypical groups, rescaled to the average
neurotypical values. The average values and the standard deviations are shown. The number of asterisks indicates the p-value (* p < 0.05, ** p
< 0.01, *** p < 0.001).
Table 7 Correlations of essential minerals in different
blood components
Comparison Autism
Group
Neurotypical
Group
Calcium WB -RBC 0.00 0.14
WB-Serum 0.40 0.33
RBC-Serum -0.30 -0.32
Magnesium WB-RBC 0.52 0.65
WB-Serum 0.41 0.34
RBC-serum 0.37 0.13
Copper WB-RBC 0.46 0.74
Zinc WB-RBC 0.65 0.84
Manganese WB-RBC 0.84 0.90
Selenium WB-RBC 0.79 0.62
Molybdenum WB-RBC 0.45 0.24
Potassium RBC-Serum -0.18 0.14
Phosphorus RBC-Serum 0.11 0.28
Iron RBC-Serum -0.03 0.13
RBC-serum ferritin -0.09 0.13
Serum- serum
ferritin
-0.08 -0.24
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Table 8 Metabolic Markers The average levels measured in the Autism and Neurotypical groups are reported below, along with their standard deviations
Units Autism
Group
Neuro-typical
Group
%
Difference
p-value Neurotypical Reference Range (10th and
90th percentiles)
Autism Group %
below RR
Autism Group %
above RR
Free Sulfate
(plasma)
μmol /
g
protein
1.44
+/- 0.51
4.09
+/- 2.28
-65% < 0.00001 * 1.4-7.5 56% 0%
Total Sulfate
(plasma)
μmol /
g-
protein
1121
+/- 212
1566
+/- 384
-28% < 0.0001 * 987-2070 36% 0%
SAM
(RBC)
μmol/
dl
214.5
+/- 15
228.4
+/- 12
-6% < 0.0001 * 210-242 39% 4%
SAH
(RBC)
μmol/
dl
44.6 +/-
8.0
42.6
+/- 4.4
n.s. 40-52 27% 24%
SAM/SAH ratio 4.9
+/- 1.1
5.4
+/- 0.6
-10% 0.006 4.1-6.0 25% 13%
Uridine
(plasma)
10-6
mol/l
15.3
+/- 7.5
7.9
+/- 2.7
+93% < 0.00001 * 5.5-10.9 4% 60%
Adenosine
(plasma)
10-8
mol/l
23.2
+/- 5.9
20.6
+/- 3.4
+12% 0.008 17-26 11% 33%
Inosine
(plasma)
10-6
mol/l
3.56
+/- 0.91
3.83
+/- 0.93
n.s. 2.7-5.2 16% 5%
Reduced plasma glutathione (GSH) nmol/
ml
3.23
+/- 0.48
4.09
+/- 0.79
-21% < 0.0001 * 3.1-5.1 53% 0%
Oxidized glutathione (GSSG) nmol/
ml
0.447
+/- 0.13
0.362
+/- 0.10
+24% 0.001 * 0.22-0.52 0% 30%
Ratio of oxidized to reduced plasma
glutathione
0.14
+/- 0.05
0.093
+/- 0.04
+49% < 0.0001 * 0.05-0.15 4% 42%
Plasma nitro-tyrosine μg/l 16.6
+/- 7.8
7.4
+/- 5.1
+125% < 0.0001 * 3.7-18 0% 44%
The p-value for a t-test comparison of the two groups is also reported. If the p-value is below 0.05, then the % difference between the groups is reported, and the result is highlighted.
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical, 10%
would be above and 10% would be below. Percentages above 25% are highlighted.
* Statistically significant difference between the two groups with 95% confidence per Bonferroni analysis.
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neurotypical reference range (urinary iodine, RBC cal-
cium) or above the neurotypical reference range (RBC
iron, RBC phosphorus, RBC boron).
We also investigated the correlations of levels of
minerals measured in different blood compartments, as
shown in Table 7. In some cases the levels correlate
strongly, but in some they do not; in the latter case
measurements for those elements need to be interpreted
cautiously as different compartments will give different
results. For magnesium, copper, zinc, manganese, and
selenium there are strong, very significant correlations
of levels between the WB and RBC, and a modest corre-
lation for molybdenum. For calcium and magnesium,
there is a significant correlation of levels in WB and
serum. For calcium, there is a small negative correlation
of RBC and serum levels. For potassium and phos-
phorus, correlations between RBC and serum are gener-
ally not significant, except possibly for a weak
correlation for phosphorus for the neurotypical group.
For iron, there are no significant correlations between
levels in RBC iron, serum iron, and serum ferritin. In
summary, interpretation of results for some elements
(magnesium, copper, zinc, manganese, and selenium) is
consistent across blood compartments, but for some ele-
ments it is not (calcium, potassium, phosphorus, iron).
Sulfation, Methylation, Glutathione, Oxidative Stress
Table 8 shows the results for sulfation, methylation, glu-
tathione, and oxidative stress markers. (11 comparisons,
so “significant” is p < 0.005, “marginally significant” is p
< 0.01, and “possibly significant” is p < 0.05). Figure 3
shows the results which were different between the aut-
ism and neurotypical groups.
Free and total sulfate in plasma were very significantly
lower in children with autism (-28% and -65%, respec-
tively, p < 0.0001).
S-adenosylmethionine (SAM, the primary methyl donor
in the body) was also very significantly lower in children
with autism vs. controls. Although the percentage difference
is not high, the normal reference range is very narrow, so
this difference is very significant. The level of SAH was not
significantly different, but it had an unusually broad distri-
bution, with 27% of the children with autism having levels
below the 10th percentile of the neurotypical group, and
24% had levels above the 90th percentile. The SAM/SAH
ratio was 10% lower in children with autism (p = 0.006).
Uridine (in plasma) was very significantly higher in the
children with autism (+93%, p < 0.0001). Uridine is
believed to be a marker of methylation status, and in
fact SAM and uridine were somewhat negatively corre-
lated (R = -0.30).
Adenosine was slightly higher (marginally significant)
in children with autism, which may indicate that some
children have an impairment in adenosine deaminase.
Reduced plasma glutathione (GSH) was very signifi-
cantly lower in the children with ASD. GSH is an
important anti-oxidant and important for excretion of
toxic metals.
All three markers of oxidative stress, namely oxidized
glutathione (GSSG), the ratio of oxidized to reduced
glutathione (GSSG:GSH), and plasma nitrotyrosine, were
very significantly higher in children with autism.
For sulfation, 36-56% of the autism group have sulfate
levels below the neurotypical reference range (see Table
8). For SAM, SAH, and SAM/SAH, 25-39% of the aut-
ism group have low levels, and 60% have elevated uri-
dine, another marker of methylation status. Adenosine
was elevated in 33% of the autism group. For reduced
glutathione, oxidized glutathione, the ratio of GSH:
GSSG, and nitrotyrosine, 30-53% of the autism group
have abnormal values.
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Figure 3 Sulfation, methylation, glutathione, and oxidative stress biomarkers which were significantly different between the autism
and neurotypical groups, rescaled to the average neurotypical values. The average values and the standard deviations are shown. The
number of asterisks indicates the p-value (* p < 0.05, ** p < 0.01, *** p < 0.001).
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Table 9 ATP, NADH, NADPH, and CoQ10 The average levels measured in the Autism and Neurotypical groups are reported below, along with their standard
deviations
Units Autism
Group
Neuro-typical
Group
%
Difference
p-value Neurotypical Reference Range (10th and 90th
percentiles)
Autism Group % below
RR
Autism Group % above
RR
ATP
(plasma)
nmol/l 14.5
+/- 4.2
18.5
+/- 4.8
-22% < 0.0001 * 13.21 36% 4%
NADH
(RBC)
nmol/
ml
15.3
+/- 4.1
20.7
+/- 4.3
-26% < 0.0001 * 16-25 51% 2%
NADPH
(RBC)
nmol/
ml
22.6
+/- 6.1
30.9
+/- 8.5
-27% < 0.0001 * 20-40 37% 2%
CoQ10
(plasma)
μg/ml 0.55
+/- 0.15
0.60
+/- 0.16
n.s. 0.4-0.8 9% 2%
The p-value for a t-test comparison of the two groups is also reported. If the p-value is below 0.05, then the % difference between the groups is reported, and the result is highlighted.
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical, 10%
would be above and 10% would be below. Percentages above 25% are highlighted.
* Statistically significant difference between the two groups with 95% confidence per Bonferroni analysis.
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ATP, NADH, NADPH, CoQ10
Table 9 shows the results for ATP, NADP, NADPH, and
CoQ10. (4 comparisons: “significant” is p < 0.012, “mar-
ginally significant” is p < 0.025, and “possibly significant”
is p < 0.05). Figure 4 shows the results which were dif-
ferent between the autism and neurotypical groups.
The primary function of mitochondria is to produce
ATP, the primary energy source in the brain and in the
body. CoQ10 is an important co-factor for mitochon-
drial function. We found that children with ASD have
levels of plasma CoQ10 that are very similar to the neu-
rotypical group. Levels of CoQ10 did not significantly
correlate with levels of ATP or with autism severity.
The autism group had much lower levels of plasma
ATP and of NADH (RBC) and NADPH (RBC), which
are the precursors to ATP, and 36-51% of the autism
group had levels below the neurotypical reference range.
The level of ATP, NADH, and NADPH were all highly
correlated with one another (r = 0.67-0.69, p < 0.001).
Plasma Amino Acids: Primary
The levels of primary (proteinogenic) plasma amino
acids are given in Table 10. Note that these are free, not
total, amino acids in plasma. (20 comparisons: “signifi-
cant” is p < 0.0025, “marginally significant” is p < 0.005,
and “possibly significant” is p < 0.05). Figure 5 shows
the results which were different between the autism and
neurotypical groups.
A few samples had abnormally low ratios of glutamine/
glutamate (< 4) and also asparagine/aspartate (< 5). These
amino acids are especially sensitive to shipping conditions,
and abnormalities in both ratios suggest that some thermal
degradation occurred during shipping/processing, result-
ing in conversion of some glutamine to glutamate, and
asparagine to aspartate. This was the case for five autism
samples and three control samples. The results for those
samples were not included in the analysis.
The autism group had significantly lower levels of
tryptophan, a precursor to serotonin, (-19%, p < 0.001)
and higher levels of glutamate, an excitatory neurotrans-
mitter (+18%, p < 0.001). There were smaller changes in
other amino acids that were possibly significant (p <
0.05), including slightly increased serine, and slightly
decreased tyrosine and phenylalanine.
For most primary amino acids, children with autism
had levels that generally lay within the neurotypical
reference ranges (see Table 10). However, there are
some cases where more than 25% of the autism group
lie below the neurotypical reference range (asparagine,
tyrosine) or above the neurotypical reference range (his-
tidine, glutamate).
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Figure 4 ATP, NADH, and NAHPH were significantly different between the autism and neurotypical groups. The average values and the
standard deviations are shown, rescaled to the average neurotypical value. The number of asterisks indicates the p-value (* p < 0.05, ** p < 0.01,
*** p < 0.001).
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Table 10 Table of Primary Amino Acids in Plasma The average levels measured in the Autism and Neurotypical groups are reported below, in units of μmol/dl,
along with their standard deviations
Amino Acids Autism
Group
Neuro-
typical
Group
%
Difference
p-
value
Neurotypical Reference Range
(10th and 90th percentiles)
Autism Group
% below RR
Autism Group
% above RR
Tietz Ref.
Range
Lepage et al Reference Range at 6
yr (top) and 16 yr (bottom)
Essential Amino
Acids
Histidine 8.84
+/- 2.0
8.2
+/- 1.3
0.06 6.4-9.8 15% 36% 6.3-9.3
7.7-10.7
Isoleucine 5.26
+/- 1.0
5.8
+/- 1.6
-9% 0.05 4.1-8.3 16% 0% 3.8-9.5
(6-18 yr,
serum)
4.0-6.9
4.7-7.4
Leucine 10.7
+/- 2.2
10.7
+/- 2.1
n.s. 8.2-13 13% 11% 7.9-17.4
(6-18 yr,
serum)
8.6-13.6
10.1-15.9
Lysine 13.5
+/- 3.8
14.5
+/- 4.8
n.s. 8.7-22 11% 2% 9.6-18.1
15.7-24.2
Methionine 1.83
+/- 0.46
1.75
+/- 0.34
n.s. 1.4-2.3 16% 13% 1.6-3.7
(6-18 yr,
serum)
1.4-2.5
2.0-3.4
Phenylalanine 4.45
+/- 0.62
4.83
+/- 0.83
-8% 0.01 3.9-6.0 20% 0% 4.8-10.9
(adult,
serum)
4.0-6.1
4.7-7.4
Threonine 9.25
+/- 2.9
8.88
+/- 2.1
n.s. 6.7-11 18% 16% 6.5-12.5
10.4-18.8
Tryptophan 3.49
+/- 1.2
4.33
+/- 1.0
-19% 0.001 * 2.7-5.6 24% 4% 3.7-7.6
5.4-9.3
Valine 19.5
+/- 3.8
20.5
+/- 4.3
n.s. 16-27 16% 4% 15.6-28.8
(6-18 yr,
serum)
16.5-23.4
17.8-27.5
Other Amino Acids
Alanine 36.4
+/-10.5
33.4
+/- 8.9
n.s. 24-45 7% 18% 19.3-54.5
(6-18 yr,
serum)
18.2-31.9
24.0-48.2
Arginine 6.50
+/- 2.4
6.7
+/- 1.8
n.s 4-9.35 16% 9% 5.0-9.9
6.8-12.8
Asparagine 4.33
+/- 1.0
4.40
+/- 0.85
n.s. 3.6-5.7 30% 8% 3.1-6.7
3.7-8.1
Aspartate 0.71
+/-0.29
0.78
+/- 0.38
0.08 0.39-1.25 8% 6% 0.3-0.6
0.2-0.5
Cystine (oxidized
form of cysteine)
3.22
+/- 0.82
3.48
+/- 0.74
n.s. 2.4-4.25 15% 11%
Glutamate 6.5
+/- 1.5
5.5
+/- 1.3
+18% 0.001 * 4.2-7.7 6% 26% 1.3-6.5
1.1-4.6
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Table 10 Table of Primary Amino Acids in Plasma The average levels measured in the Autism and Neurotypical groups are reported below, in units of ?μ?mol/
dl, along with their standard deviations (Continued)
Glutamine 43.3
+/- 9.0
41.6
+/- 6.9
n.s. 34-52 16% 20% 36-74
(6-18 yr,
serum)
49.3-72.4
55.1-79.7
Glycine 26.7
+/- 8.1
27.3
+/- 10.1
n.s. 16-39 4% 6% 14.4-28.2
18.3-32.2
Proline 15.7
+/- 5.5
15.8
+/- 4.9
n.s. 11.5-24 20% 7% 9.3-20.1
11.3-27.1
Serine 10.4
+/- 2.5
9.47
+/- 2.1
+10% 0.04 6.9-12 5% 15% 9.6-15.5
10.1-17.7
Tyrosine 5.51
+/- 1.2
6.1
+/- 1.6
-10% 0.03 4.8-8 31% 4% 4.4-7.2
(adult)
3.9-6.5
4.6-8.7
The p-value for a t-test comparison of the two groups is also reported. If the p-value is below 0.05, then the % difference between the groups is reported, and the result is highlighted.
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical, 10%
would be above and 10% would be below. Percentages above 25% are highlighted. Reference Ranges from Tietz Textbook of Clinical Chemistry are given for serum amino acids where available. For Lepage et al, the
reference ranges are the 10th and 90th percentiles for ages 6 yr and ages 16 yr.
* Statistically significant difference between the two groups with 95% confidence per Bonferroni analysis.
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Plasma Amino Acids: Secondary
The levels of secondary plasma amino acids and amino
acid metabolites are given in Table 11. Cystathionine
was also measured, but all the measurements except 1
were below the detection limit of 0.05 umoles/100 ml,
so those values are not listed. (21 comparisons: “signifi-
cant” is p < 0.002, “marginally significant” is p < 0.005,
and “possibly significant” is p < 0.05). Figure 5 shows
the results which were different between the autism and
neurotypical groups.
The autism group had a higher level of beta-amino
isobutyrate (+39%, p = 0.004, marginally significant).
They had a possibly significant lower level of taurine.
They also had a possibly significant much higher level
of “homocystine + homocysteine"- however, it should be
noted that 71% of the autism group and 89% of the neu-
rotypical group had levels below the detectable limit, so
the “homocystine + homocysteine” results should be
interpreted with caution.
For the secondary amino acids, children with autism
had levels that generally lay within the neurotypical
reference ranges (see Table 11). However, there were
some cases where more than 25% of the autism group
lay below the neurotypical reference range (citrulline,
phosphoethanolamine) or above the neurotypical refer-
ence range (phosphoserine).
Medication Effects
45% of the children with autism were taking one or
more medications (see Table 1). Some of those medica-
tions may have affected their levels of vitamins, miner-
als, or other biomarkers. Some psychopharmaceuticals
(such as risperidone and clonidine used by several of
this ASD population) and anti-convulsants (valproic acid
and topiramate used by two of the ASD subjects) are
known to interfere with nutrient levels and gastrointest-
inal function in a variety of ways. Anticonvulsants may
interfere in energy production [40] and folate metabo-
lism and for some in levels of vitamin D. Valproate, a
known teratogen [41,42] and hepatotoxin [42] as studied
in humans and animals increases GABA in the brain
and is a folate antagonist with absorption not affected.
In animal studies [43] valproate has been shown to
increase oxidative stress as methionine and vitamin E
mitigate teratogenic effects. Valproate inhibits histone
deacetylases, increasing accessibility of DNA to
demethylases resulting in altered gene expression. In
humans valproate may increase plasma ammonia,
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Figure 5 Amino Acids which were significantly different between the autism and neurotypical groups, rescaled to the average
neurotypical value. The average values and the standard deviations are shown. The number of asterisks indicates the p-value (* p < 0.05, ** p
< 0.01, *** p < 0.001). The standard deviations for beta-amino-isobutyrate and “homocystine + homocysteine” are outside the margins of the
figure.
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Table 11 Secondary Plasma Amino Acids and their metabolites, in units of μmol/dl
Amino Acids Autism
Group
Neuro-typical
Group
%
Difference
p-
value
Neuro-typical Ref. Range (10th and 90th
percentiles)
Autism Group % below
RR
Autism Group % above
RR
1-Methyl histidine 0.365
+/- 0.15
0.355
+/- 0.12
n.s. 0.19-0.52 11% 15%
3-Methyl histidine 0.74
+/- 0.68
0.68
+/- 0.52
n.s. 0.20-1.4 13% 20%
Alpha-amino adipate
(33%/27% below dl)
0.079
+/- 0.32
0.088
+/- 0.044
n.s. 0.05-0.17 0% 0%
Alpha-amino-N-butyrate 1.78
+/- 0.66
1.82
+/- 0.72
n.s. 1.0-2.8 11% 7%
Anserine
(85%/95% below dl)
0.058
+/- 0.027
0.051
+/- 0.006
0.06 0.32-1.0 11% 11%
Beta-alanine 0.60
+/- 0.28
0.62
+/- 0.31
n.s. 0.05-0.26 0% 15%
Beta-amino isobutyrate 0.191
+/- 0.89
0.138
+/- 0.088
+39% 0.004 2.45-3.75 25% 20%
Carnosine
(76%/89% below dl)
0.061
+/- 0.031
0.054
+/- 0.015
n.s. 2.4-4.3 15% 11%
Citrulline 3.02
+/- 0.80
3.02
+/- 0.52
n.s. 0.31-1.55 9% 18%
Cystine + Cysteine 3.22
+/- 0.82
3.48
+/- 0.74
n.s. 1.3-3.6 5% 5%
Ethanolamine 1.07
+/- 0.75
0.94
+/- 0.63
n.s. 0.13-0.65 2% 9%
Gamma-amino butyrate
(75%/84% below dl)
0.053
+/- 0.006
0.053
+/- 0.008
n.s. 3.9-8.3 9% 5%
Homocystine +
Homocysteine
(71%/89% below dl)
0.0094
+/- 0.010
0.0055
+/- 0.0016
+71% 0.006 0.87-2.2 25% 13%
Hydroxy proline 2.40
+/- 0.80
2.19
+/- 0.80
n.s. 0.0085-0.022 5% 33%
Methionine Sulfoxide 0.368
+/- 0.20
0.315
+/- 0.21
n.s. 0.4-1.35 13% 5%
Ornithine 5.9
+/- 1.6
5.98
+/- 1.7
n.s. 5.3-23.5 4% 4%
Phospho ethanol amine 1.34
+/- 0.73
1.55
+/- 0.59
n.s. 195-400 2% 3%
Phospho serine 0.045
+/- 0.078
0.024
+/- 0.044
n.s.
Sarcosine 0.80
+/- 0.32
0.893
+/- 0.36
n.s.
Taurine 13.9
+/- 5.8
16.8
+/- 5.8
-17% 0.02
Urea 299
+/- 94
309
+/- 87
n.s.
In some cases data was below the detectable limit -if this was greater than 20%, then we report the data as the % of the autism group and then the % of the neurotypical group below the detectable limit (dl).
The table also lists the reference range of the neurotypical group (10th and 90th percentiles), and the % of the Autism group who are above or below the reference ranges. Note that if the groups were identical, 10%
would be above and 10% would be below. Percentages above 25% are highlighted.
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homocysteine and glutamine and decrease carnitine [42].
Topiramate may create metabolic acidosis, decrease glu-
tamate and increase GABA. The effect upon specific
nutrients has not been as well studied for the psycho-
pharmaceuticals [44].
To investigate if medication use had a significant
effect on results, a t-test comparison was made between
the autism group taking medications (45%) vs. the aut-
ism group not taking any medications (55%). The only
differences with a p-value less then 0.01 were lower
RBC copper (-9% lower, p = 0.001) and higher plasma
methionine sulfoxide (+35% higher, p = 0.002) for the
autism medication group compared to the autism no-
medication group. So, aside from those two differences,
it appears that medication use had little effect on the
results.
Correlations with Autism Severity
The correlations of each biomarker with each of the
three autism severity scales were calculated. Table 12
lists the biomarkers which had the highest correlation
with autism severity (r > 0.34 in absolute magnitude,
corresponding to a p value of 0.01 or lower). The bio-
markers had p < 0.01 for only one autism severity scale
at most. Given multiple biomarkers, the cut-off for sig-
nificance is below p = 0.001. So, none of the results are
significant, but some have p < 0.01 and are worth
further investigation.
Regression Analyses
Regression analysis develops an equation that relates
one or more “independent” variables (such as metabolic
biomarkers) to a single “dependent” variable (such as
severity of autism). The regression equation has coeffi-
cients that minimize the differences between observed
values of the dependent variable and those predicted by
the equation. The standard measure of how well a
regression performs is R2, which is the proportion of the
variation in the dependent variable that can be
explained by the regression. (If R2 = 1, the regression
equation fits the dependent variable perfectly; if R2 = 0
the independent variables provide no useful information
about the dependent variable).
Vitamins
The regression analysis yielded a significant result for all
three autism severity scales (adj. R2 of 0.25-0.57), with
the highest adjusted R2 for the PDD-BI. Vitamin B6,
Vitamin C, N-methyl-nicotinamide, and Vitamin K were
the most consistently significant variables.
Minerals
The regression analysis yielded a significant result for all
three scales (adj. R2 of 0.22-0.38), with the highest
adjusted R2 for the PDD-BI. Calcium (RBC), Iron (RBC),
Zinc (WB and RBC), and Potassium (RBC) were the
most consistently significant variables. Note that almost
all of the most consistently significant variables were in
RBC; ie, it is the RBC levels that seem to be most
strongly associated with autism severity.
Sulfation, Methylation, Glutathione, Oxidative Stress
The regression analysis yielded significant results for all
three scales, with all three severity scales having modest
adjusted R2 (0.15-0.24). Free Sulfate was the most con-
sistently significant variable, followed by Oxidized Glu-
tathione and SAM.
ATP, NADH, NADPH, CoQ10
The regression analysis yielded significant results for
only one severity scale (the ATEC), with only a modest
adjusted R2 (0.15). NADH and ATP were the two signif-
icant variables.
Primary Amino Acids
The regression analysis yielded significant results for all
three scales (adj. R2 of 0.22-0.39), with the PDD-BI hav-
ing the highest adjusted R2. Proline and Serine were the
most consistently significant variables.
Secondary Amino Acids
The regression analysis yielded significant results for all
three scales, with modest adjusted R2 (0.18-0.26). Etha-
nolamine and Beta-amino-isobutyrate were the most
consistently significant variables.
Overall Analysis
This analysis involved starting with all variables from
the previous analyses that were significant in one or
more of the subgroup analyses (p < 0.01), determined
individually for each autism severity scale. The Overall
regression analysis yielded highly significant results for
all three scales (p < 0.002 or better for all cases), with
the highest adjusted R2 for the PDD-BI, followed by the
SAS and then the ATEC. Different markers were signifi-
cant for different autism severity scales.
Discussion
Overview
The general agreement of the present neurotypical refer-
ence ranges of many vitamins, minerals, and primary
Table 12 Correlation of Biomarkers with the modified
PDD-BI Autism Composite, ATEC, and SAS, with the
correlation coefficient followed by the p-value in
parentheses
PDDBI ATEC SAS
Plasma Free Sulfate -0.19 (n.s.) -0.25 (n.s.) -0.38 (0.006)
RBC Iron 0.36 (0.009) 0.27 (0.05) 0.12 (n.s.)
Serum Phosphorus 0.38 (0.006) 0.11(n.s.) 0.12 (n.s.)
Plasma Phenylalanine -0.22 (n.s.) -0.29 (0.03) -0.43 (0.002)
Only biomarkers with values of R = 0.34 or greater are listed, corresponding
to a p-value of 0.01 or lower. Note that since many correlations were
investigated, these results are not highly significant, and are at most possibly
significant.
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amino acids with published reference ranges from stan-
dard sources provides validation of the methodology
used. Children with autism have mean levels of vita-
mins, minerals, and most primary amino acids that gen-
erally lie within published reference ranges. In the care
of children with autism, the practitioner is therefore
unable to discern emerging metabolic dysfunction or
utilize measured values of these standard analytes as the
basis for clinical decision-making regarding supplemen-
tation in most cases. More reliable and of greater clini-
cal significance are levels of sulfation, SAM, uridine,
glutathione, oxidative stress, and ATP/NADH/NADPH
which are very likely to be abnormal.
In the sections below we provide a detailed discussion
of each of the categories of measurements. However,
some of the results are inter-related, so we wish to first
discuss some of the major results.
Sulfation and ATP
Children with autism had significantly lower levels of
plasma sulfate, including both free and total sulfate,
consistent with several previous studies. ATP is required
in the kidney to resorb sulphate (recycling of sulphate is
important because sulphate is poorly absorbed from the
gut, and conversion from cysteine is slow). This study
found a significant correlation of ATP with free and
total plasma sulphate (r = 0.32 and 0.44, respectively),
suggesting that decreased ATP is a significant contribu-
tor to decreased sulphate levels in children with autism.
Methylation and ATP
Children with autism had significantly impaired methy-
lation, as evidenced by low levels of SAM (the primary
methyl donor) and high levels of plasma uridine (which
requires methylation to be converted to thymidine).
SAM is formed from methionine by methionine adenyo-
syl transferase, which requires ATP. Methionine levels
were similar in the autism and neurotypical groups, but
ATP levels were very significantly lower in the autism
group, suggesting that low levels of ATP are at least
part of the reason for decreased levels of SAM. Methio-
nine in the body comes partially from the diet (it is an
essential amino acid) and partially by the recycling of
homocysteine to methionine (via methionine synthase
or methyl transferase). Methionine synthase requires
methyl-B12 and 5-methyl-tetrahydrofolate, a derivative
of folic acid. Both vitamin B12 and folic acid were simi-
lar in the autism and control groups, consistent with
normal levels of methionine. Normal levels of methio-
nine are consistent with one previous study [10] which
involved the use of age-matched controls with no intake
of vitamins/minerals; previous studies of methionine
levels had reported significant differences, but those stu-
dies involved either children with autism taking a vita-
min/mineral supplement [8] or significant age
differences [9].
Oxidative Stress
Children with autism had significantly elevated oxidative
stress, as indicated by increased GSSG/GSH ratio (glu-
tathione is the primary anti-oxidant in the body), and
increased plasma nitrotyrosine. GSSG is reduced to
GSH by glutathione reductase, which requires NADPH.
NADPH levels were substantially lower in children with
autism, which would explain why they also had a
decreased GSH/GSSG ratio. These results are consistent
with several previous studies discussed in the
Introduction.
Vitamins
The data show that, on average, children with autism
have lower levels of biotin, and trend toward lower
levels of vitamin B5, vitamin E, and total carotenoids.
Those nutrients were also more likely to be below the
reference range of the neurotypical group. The autism
group had somewhat higher levels of vitamin C.
The broad distribution of vitamin B6 (measured as the
active form, P5P, inside the RBC) is very interesting.
Two previous studies [45,46] found high levels of total
B6 in the plasma, and in those papers it was hypothe-
sized that it might be due to an impaired conversion of
B6 to the active form, P5P. That hypothesis may be
valid for the subset of children with low RBC P5P, but
there also appears to be a subset with high RBC P5P.
Overall, the broad distribution of RBC P5P suggests that
there is a subset of children who need more vitamin B6,
and a subset who have high levels of B6. This is consis-
tent with 11 double-blind, placebo-controlled studies
which mostly found that about half of children or adults
with autism benefit from mega-doses of vitamin B6
(500-1000 mg, or 250-500× the RDA) [45]. This study
suggests that there may be a subgroup (those with low
RBC P5P) who would likely benefit from B6 supplemen-
tation. However, since B6 levels are not dramatically
low, it is possible that high doses (20-40× RDA) instead
of mega-doses (100-250× the RDA) might be sufficient,
unless P5P-dependent enzymes are highly defective and
require very high levels of P5P to function normally.
The higher level of total choline in the children with
autism is interesting, and may suggest an impairment in
conversion of choline to acetylcholine.
There is current interest in the role of Vitamin D in
not only bone metabolism but also immune system
function [47]. D3, synthesized in the skin on exposure
to sunlight, and D2, supplied in plant and fungi based
foods, are both prohormones for 25-OH-D which was
measured in this study. The role of vitamin D in autism
[48,49] has begun to receive attention. In this current
study there was no difference in plasma vitamin D levels
in children with autism versus controls. Measured levels
for the neurotypical children were consistent with the
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results of the NHANES US population study. In both
study groups there is a subgroup, which is borderline or
below published RR, even in a geographic location (Ari-
zona) with potential for high sun exposure. The cause
for the decreased vitamin D levels in the general popula-
tion is not well understood; it is likely multifactorial.
One known factor is the change in modern lifestyles
which have resulted in less exposure to direct sunlight.
Thus, the “average” level of the general population may
not be “optimal.” So, it may be that most children,
including children with ASD, may benefit from more
vitamin D. The present results somewhat differ with a
study in Egypt [19], which found that young children
with autism (5.3 +/- 2.8 yr) had significantly lower levels
of 25 (OH)D (28.5 +/- 16.4 mcg/l) than did controls
(40.1 +/- 11.8 mcg/l) of similar age. The levels for the
autism group for the Egyptian and the present study are
in close agreement; however the Egyptian normative
control levels are much higher than for the present
study. To determine if the difference with the present
results was partially due to differences in study age, the
present data for children ages 5-10 years was analyzed,
but found no difference between the autism and control
groups. So, the difference appears to be due to differ-
ences in the control groups and may reflect differences
in entire population reference ranges, perhaps due to a
variety of factors, such as sun exposure, dietary intake
or factors interfering in vitamin D metabolism.
It is interesting to compare the results of this study
with other studies. The following findings for children
with autism relative to controls are consistent with
other studies: lower vitamin E [15,20]; normal levels of
vitamin B12 [11,50], serum folate [11,50] and vitamin A
[20]. The present finding of increased vitamin C is con-
sistent with one study [20], but inconsistent with
another study that found normal levels of vitamin C
[15]. The present finding of slightly lower levels of total
carotenes is in contrast to a study [15] in Saudi Arabia
which found greatly increased levels of beta carotene;
the reason for that difference is unclear (typically 80% of
total carotene is beta-carotene, but may be due to differ-
ences in which nation the study was conducted in, due
to differences in ethnicity, diet, and other factors. Fast-
ing status is also important, as food intake rapidly
affects levels of most vitamins.
Functional tests
FIGLU is an intermediate in the deamination of histi-
dine. Conversion of FIGLU to glutamic acid is the 4th
step in this process and requires the enzyme formimino-
transferase and the co-factor folic acid. The elevated
urinary FIGLU suggests deficiency in either the enzyme
or in folic acid. Plasma folic acid was slightly lower in
the autistic group but the difference was not significant.
Plasma folic acid did not significantly correlate with
FIGLU levels. As a water soluble vitamin, folic acid var-
ies daily with intake. FIGLU excretion may be represen-
tative of a longer metabolic period. FIGLU may be a
more sensitive indicator of need for folic acid than mea-
surements of plasma folic acid.
N-methyl-nicotinamide is a metabolite of vitamin B3
(niacin). The finding of higher levels of urinary n-
methyl-nicotinamide in the autism group (possibly sig-
nificant) is consistent with another study [51] which
found elevated urinary n-methyl-nicotinamide in chil-
dren with autism compared to neurotypical children.
Whole blood niacin levels were very similar in the aut-
ism and neurotypical groups, and whole blood niacin
levels did not significantly correlate with n-methyl-nico-
tinamide levels, which suggests that n-methyl-nicotina-
mide is a more sensitive assay.
Children with autism had normal levels of kryptopyr-
oles in urine, although a few outliers raised their stan-
dard deviation. The measurements of kryptopyroles
should not be confused with measurements of the
“mauve factor” which was once thought to be kryptopyr-
ole but is actually hydroxyhemopyrrolin-2-one (HPL)
[52].
Minerals
The much lower level of WB lithium is consistent with
a previous study [21], which found lower levels of
lithium in younger children with autism and their
mothers, but not in the older children. Those measure-
ments were done in hair, which appears to be a more
sensitive measure than blood, based on a study of
lithium-deficient animals [53]. Animals fed a lithium-
deficient diet had decreased immune function and suf-
fered from more chronic infections, which may partially
explain why several studies have found that children
with autism have significantly more ear infections than
typical children [54-57]. Lithium-deficient animals also
had decreased activity of monoamine oxidase, which can
greatly affect neurotransmitter levels. Low levels of
lithium are associated with a wide range of psychiatric
disorders [58]. The primary biochemical effect of lithium
is that it regulates two enzymes, glycogen synthase
kinase 3-beta and phosphatidylinositol phosphatase,
both of which have been linked to autism [59,60]. Both
enzymes are involved in the growth factor signaling
pathway (PI3-kinase). Low levels of lithium are of con-
cern and these results suggest that low-level lithium
supplementation may be beneficial for mood stabiliza-
tion in this group. Along with other studied nutrients,
the role lithium plays in the etiology of autism warrants
further study.
Serum iron and serum ferritin were similar in the aut-
ism and neurotypical groups. A previous study [22]
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found that 8 of 96 American children with ASD were
anemic (haemoglobin < 110 g/l). In that study, the age
range of the general group was 3-13 yr, but 7 of the 8
autism cases were in children under age 5. Another
study [23] found that 16% of 96 Canadian children with
ASD ages 1-10 yr had low serum ferritin (< 10-12 mcg/
L), with little effect of age. The present study of older
children with ASD (ages 5-16 yr) found only 2% of the
children had serum ferritin levels below 12 mcg/L,
which is roughly consistent with the results for older
children in the study by Latif et al [22], but somewhat
lower than the rate found in the study by Dosman et al
2006 [23]. Combining the results of all three studies,
anemia seems to be a common problem in young chil-
dren with autism (below age 5), but perhaps less com-
mon in older children with autism, likely consistent
with the general population.
There was a slightly higher, but statistically significant,
RBC iron in the autism group. The clinical significance
of elevated RBC iron is unclear, but it did correlate with
autism severity (for the PDD-BI), so elevated RBC iron
may be problematic. This finding did not correlate with
oxidative stress in this study; further research is
warranted.
Most other minerals were only slightly different in the
autism group compared to the control group. The
slightly higher level of copper (WB and RBC) suggests
most children with autism do not need copper supple-
mentation. The slightly lower (possibly significant) level
of magnesium in serum and WB suggests that modest
magnesium supplementation might be beneficial, but
RBC magnesium was normal, so at most this suggests
only a minor need. The possibly significant slightly
higher levels of RBC potassium, RBC phosphorus, and
RBC boron seem to be minor fluctuations, and may be
a statistical artifact.
The autism group had an average level of urinary
iodine that was similar to the average level of the neuro-
typical group, but 25% of the autism group had urinary
iodine levels that were below the 10th percentile of the
neurotypical group. 14% of the autism group and 11% of
the control group had insufficient iodine (< 100 ng/ml)
based on the WHO 2007 criteria, although this needs to
be interpreted cautiously since those children also had
lower creatinine levels (more dilute urine) and the
WHO criteria is based on volume, not normalized by
creatinine, since they are focused on population ana-
lyses, not individual analyses. A previous study [21]
found significantly lower levels of iodine in hair of chil-
dren with autism compared to controls. It is unknown if
hair levels are indicative of iodine status, whereas urin-
ary levels are accepted as the best measure of iodine sta-
tus, as most iodine is excreted in the urine [61]. Overall,
it does appear that there is a significant subset of
children with autism with low levels of iodine, which is
one of the leading causes of mental retardation world-
wide [61], and we believe that further investigation of
iodine status and thyroid status is warranted.
It is interesting to compare our results with a smaller
study of RBC minerals in young Canadian children with
autism (n = 20) compared to neurotypical children (n =
15), both with average ages of 3.9 years [24]. That study
found lower levels of RBC selenium (p = 0.0006), higher
levels of RBC molybdenum (p = 0.01), and possibly
lower levels of RBC zinc (p = 0.08). They found similar
levels of chromium, copper, magnesium, and manganese
in RBC in the two groups. This smaller study partially
agrees with the present study (normal levels of RBC
chromium, magnesium, manganese), but partially dis-
agrees in that the present study did not find a difference
in RBC selenium, molybdenum, or zinc, and possibly
found slightly higher RBC copper. Part of the difference
in study results may be due to differences in ages
(averages of 4 yr vs. 10 yr), geographic/dietary issues
(Canada vs. Arizona), and study size.
A study [25] of copper and zinc levels of 20 British
older children with autism compared to 30 British older
neurotypical children did not find any significant differ-
ence in zinc or copper levels in plasma, although the
autism group did have a 10% higher level of copper,
similar to the present results for WB zinc (no differ-
ence) and WB copper (7% higher, p = 0.02).
A study of zinc levels in 45 children with ASD age 4-
12 years compared to 41 neurotypical controls of similar
age in Turkey found lower levels of zinc in WB and
RBC [26]. This disagrees with the British study [25] and
the present US study, possibly due to difference in cul-
ture/diet/geographical area.
Sulfation, Methylation, Glutathione and Oxidative Stress
Sulfate is the third most abundant essential mineral in
the body. Roughly 80% of sulfate is produced in vivo by
oxidation of methionine or cysteine, both sulphur-con-
taining amino acids which are provided from dietary
proteins. Sulfation is important for many reactions
including detoxification, inactivation of catecholamines,
synthesis of brain tissue, sulfation of mucin proteins
which line the gastrointestinal tract, and more. The
measurement of total plasma sulfate involves many sub-
stances in the plasma, including neurotransmitters, ster-
oids, glycosaminoglycans, phenols, amino acids,
peptides, and other molecules. The findings of very low
free and total plasma sulfate are consistent with two stu-
dies, which found decreased plasma sulfate compared to
neurotypical controls [62,63]. Low sulfate in the plasma
is also consistent with four studies [62,64-66] which
found that children with ASD had a significantly
decreased sulfation capacity compared to controls, based
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on low levels of the paracetamol-sulfate/paracetamol-
glucuronide (PS/PG) ratio in urine following administra-
tion of paracetamol (acetaminophen, trade name of
Tylenol). The finding of low plasma sulfate is also con-
sistent with a large study that found high sulfate in the
urine of children with autism [67], as sulfate wasting in
the urine partly explains low levels in the plasma. ATP
is required for the kidneys to resorb sulfate, and in this
study ATP was correlated with levels of free and total
plasma sulfate (r = 0.32 and 0.44, respectively), so this
suggests that low levels of ATP are a significant contri-
butor to decreased sulfate in children with autism. That
paper also reported high levels of urinary sulfite, sug-
gesting that there was a problem of converting sulfite to
sulfate in the mitochondria. In 38% of cases (14/38)
urinary sulfite and sulfate levels improved by giving 50
mcg of molybdenum, presumably since the enzyme for
converting sulfite to sulfate (sulfite oxidase) contains
molybdenum. In this study there was a weak correlation
(r = 0.24) of RBC molybdenum with plasma free sulfate,
but no significant correlation with plasma total sulfate.
The findings of decreased reduced glutathione (GSH),
increased oxidized glutathione (GSSH), and increased
ratio of oxidized:reduced glutathione are consistent with
four previous studies [8-10,63]. The finding of decreased
SAM in RBC is consistent with three studies of SAM in
plasma [8-10]. Our finding of an unusually broad distri-
bution of SAH in RBC only slightly higher (+5%, n.s.)
than that of controls is similar to that of one study [10]
which also found a slightly higher level of SAH in
plasma (+6%, n.s.), but different from two other studies
which found higher levels of SAH in plasma [8,9]. It
should be noted that we measured SAM and SAH in
RBC, whereas the other studies [8-10] measured SAM
and SAH in plasma; RBC levels are far greater than
plasma levels, but seem to provide similar results for
children with autism vs. controls.
SAM is converted to SAH by the transfer of a
methyl group, so the ratio of SAM/SAM is a measure
of the body’s methylation capacity. The finding of a
slightly decreased SAM/SAH ratio (-10%, p = 0.006) is
similar to one study [10] which found a slightly
decreased level (-17%, n.s.), and similar to two other
studies [8,9] which also found decreased levels of
SAM/SAH; however, those two studies found a larger
decrease (-44% and -27%, respectively) in the SAM/
SAH ratio than in this study, due to lower levels of
SAM.
The finding of very elevated plasma uridine suggests
impaired methylation (methylation is required for con-
version of uridine to thymidine), consistent with the
decreased level of SAM.
The finding of elevated plasma adenosine in 33% of
the autism group is consistent with two previous studies
[8,9] and suggests an impairment in adenosine deami-
nase since adenosine levels are normal. Adenosine binds
to the active site of SAH hydrolase and inactivates it
[68,69] so elevated adenosine would block conversion of
SAH to homocysteine, and hence may partially explain
the decreased SAM/SAH ratio.
The finding of increased nitrotyrosine shows that this
is also a good marker for oxidative stress in children
with autism, and is consistent with the other measure-
ments of oxidative stress (oxidized glutathione and ratio
of oxidized:reduced glutathione).
Overall, the problems with SAM, glutathione, and oxi-
dative stress suggest that children with autism need
increased anti-oxidant support, folinic acid (not folic)
and vitamin B12 to support the methionine cycle. (Folic
acid is not sufficient in most cases. In the James et al
2004 [8] study 16 of the 20 children with autism were
taking a multivitamin and mineral supplement contain-
ing 400 ug folic acid and 3 ug vitamin B-12 but still had
abnormal methylation; folinic acid, not folic acid, was
needed to normalize methylation).
ATP, NADH, NADPH, CoQ10
The finding of decreased plasma ATP, NADH, and
NADPH, but normal levels of their precursor (vitamin
B3- niacin) may suggest an impairment in the formation
of NADH from niacin. The clinical significance of
decreased levels of ATP in the plasma is unclear, since
most ATP is intracellular. Impaired transport of ATP
throughout the body is suggested. ATP is the primary
energy source for many metabolic reactions, and
decreased levels of plasma ATP may be related to
decreased muscle tone and decreased endurance com-
monly observed in children with autism [21,70] NADH
is mainly involved in catabolic reactions (energy meta-
bolism and mitochondrial function) whereas NADPH is
involved in anabolic reactions (antioxidation and reduc-
tive biosynthesis) [71]. Decreased plasma ATP and
NADH may also relate to impaired mitochondrial func-
tion, which has been reported in some children with
autism [72-75].
The reason for the decreased ATP, NADH, and
NADPH is unclear. ATP, NADH, and NADPH were all
strongly correlated with one another (r = 0.67 = 0.69),
and all had a significant correlation with ratio of GSSH:
GSG (r = -0.34 to -0.52), and plasma nitrotyrosine (r =
-0.24 to -0.51) indicating that increased oxidative stress
is associated with low ATP, NADH, and NADPH.
Increased oxidatative stress would result in a significant
conversion of NADH to NAD+ (which was not mea-
sured in this study). This could also be true to a limited
extent for NADPH, but usually NADP+ is only a very
small fraction of NADPH. It also may be due to
impaired function and/or amount of translocator protein
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in the mitochondrial membrane, which would impair
transport of ATP from the mitochondria into the cyto-
plasm [76] and into the plasma.
Primary Amino Acids
One significant abnormality in the plasma amino acids
was elevated glutamate in the ASD group. Glutamate is
the most prominent neurotransmitter. It is ubiquitous
throughout the central nervous system where it modu-
lates synaptic plasticity, vital to memory, learning and
regulation and modulates gene expression, functioning
in post-synaptic excitation as well as some inhibition.
Overstimulation leads to excitotoxicity, creating oxida-
tive stress, mitochondrial damage and ultimately may
play a role in neurodegeneration. Peripherally it plays a
role in taste, skin pain sensation and pancreatic exocrine
function. Increased glutamate may be linked to some of
the behavioral problems and features commonly asso-
ciated with autism. It may indicate an increased need
for vitamin B6, needed for conversion of glutamate to
glutamine.
Another significant abnormality was decreased trypto-
phan in the ASD group. This may be due to decreased
protein intake, and/or impaired digestion of protein into
amino acids; the latter seems more likely since most of
the essential amino acids were normal. Tryptophan is a
precursor to the synthesis of serotonin, so decreased
tryptophan is likely to impair serotonin synthesis
(important in neurogenesis and neurotransmission). The
importance of low tryptophan in autism was demon-
strated by a randomized, double-blind, placebo-con-
trolled crossover study that found that a 24-hour-diet
low in tryptophan followed by a tryptophan-deficient
amino acid drink led to a significant worsening in beha-
vior in adults with autism [77].
There were several other differences which were only
possibly significant (p < 0.05). The ASD group also had
slightly increased serine, and slightly decreased phenyla-
lanine and tyrosine. The low tyrosine is presumably due
to the low phenylalanine, since tyrosine is derived from
phenylalanine, and they were highly correlated with one
another (r = 0.74). The low phenylalanine could be due
to decreased protein intake and/or impaired digestion of
protein into those amino acids.
Our results suggest that some children with autism
(those with low tryptophan and phenylalanine) would
benefit from either increased protein intake, use of
digestive enzymes containing proteases, and/or supple-
ments of tryptophan (or 5-HTP) and phenylalanine.
Two previous studies by James et al [8,9] found
decreased plasma methionine in children with autism vs.
controls, but their most recent study [10] did not; the
latter is consistent with the present study, which did not
find a significant difference in plasma methionine.
Although there have been several other studies of
plasma amino acids in children with autism, they suf-
fered from one or more limitations, including small
sample size, no fasting requirement, lack of neurotypical
controls, and/or age differences between the autism and
control groups, and thus have not surprisingly yielded
contradictory results to one another, and to the present
results.
Overall, the present data on plasma amino acids
appears to be more reliable than most of the other stu-
dies of plasma amino acids, due to its larger size, over-
night fast, use of neurotypical controls, use of controls
of similar age, and simultaneous testing of autism and
control groups. The present results suggest that children
with autism, on average, have lower levels of plasma
tryptophan, increased plasma glutamate, and possibly
lower levels of several other amino acids.
Secondary Amino Acids
The only significant abnormality in the secondary amino
acids was increased beta-aminoisobutyrate (also known
as 3-aminoisobutyric acid) in the autism group. Beta-
aminoisobutyrate is a product formed by the catabolism
of thymine, one of the four nucleobases in the nucleic
acid of DNA. So, elevated beta-aminoisobutyrate may
indicate an increased rate of DNA turnover, and/or it
may indicate an inhibition of the conversion of beta-
aminoisobutyrate into the intermediates that eventually
lead to the citric acid cycle.
There was also a possibly significant lower level of
taurine, which could be due to an impairment of the
conversion of methionine to cysteine to taurine, but it
could also be due in part to increased wasting of taurine
in the urine, which has also been reported [78]. This is
consistent with another study [63], which also found
low plasma taurine in children with autism, although
that study found a greater difference.
For “homocystine + homocysteine”, it was undetect-
able in most cases, but it was detectable in a higher
fraction of the autism group (29%) vs. the control group
(11%), suggesting a possible abnormality in metabolism
of homocystine and/or homocysteine in some children,
but due to measurement limitations this requires inves-
tigation with more sensitive techniques that do not oxi-
dize the homocysteine.
Potential Confounding Factors: Medication,
Gastrointestinal and Dietary Issues
45% of the autism group were taking medications, and
some of those can affect nutritional status, metabolism,
and gastrointestinal function. However, a t-test com-
parison of the two groups revealed only two small dif-
ferences between the autism groups taking and not
taking medications, so medication use appeared to
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have little effect on the results reported here. Many of
the autism group had gastrointestinal problems, either
separate from or secondary to medications being
taken, which may have affected nutritional intake. As
shown in Table 1, 18% of the autism group had mod-
erate or severe diarrhea, and 41% had moderate or
severe constipation (9% of the total participants had
both moderate or severe diarrhea and constipation,
apparently alternating between them). Also, 53% of the
children had moderate or severe problems with self-
restricted diets (only interested in eating a few foods,
often resulting in poor nutritional intake). Finally, 16%
of the children with autism were on special diets (see
Table 1), which could result in some differences in
nutritional status.
Correlation Analysis
In most cases the sign of the correlation analysis is con-
sistent with our understanding. For example, low
amounts of an essential mineral (sulfate) or essential
amino acid (phenylalanine) correlated with more severe
autism. The positive correlation of RBC iron with aut-
ism severity suggests that excess RBC iron requires
further research. Excess iron could increase oxidative
stress through the Fenton reaction, in which iron cata-
lyzes the conversion of hydrogen peroxide into two
hydroxyl radicals and water.
Regression Analysis
It is very interesting that almost all of the biomarker
groups have significant associations with variation in
autism severity. Vitamins (especially vitamin B6, vitamin
C, and n-methyl-nicotinamide) had a very high adjusted
R2 for the PDD-BI (0.57) (see Table 13). Minerals (espe-
cially calcium, iron, and zinc) had moderate adjusted R2
(0.22-0.38), as did the primary amino acids (adjusted R2
of 0.22-0.38) (see Table 13). Secondary amino acids and
the group of Sulfation/Methylation/Glutathione/Oxida-
tive Stress had significant but only modest adjusted R2
(0.15-0.26) (see Table 14 and 15). The group of ATP/
NADH/NADPH/CoQ10 had a significant association for
only one of the three severity measures (see Table 14).
So, overall, it seems that certain vitamins, minerals,
amino acids, and (to a lesser extent) other biomarkers
have significant associations with variations in the sever-
ity of autism (see Table 16).
The Overall analysis yielded very significant associa-
tions with the variation in autism severity, especially
for the PDD-BI, followed by the SAS and then the
ATEC. The most significant biomarkers were generally
different for each autism severity instrument, but this
is not surprising since some biomarkers have signifi-
cant correlations with one another, and small differ-
ences can lead to one biomarker replacing another in
the analysis. Rather than focusing on a particular
Table 13 Regression Analysis for Autism Severity vs. Vitamins (and related metabolites) and Minerals
PDD-BI ATEC SAS
Vitamins
Adjusted R2 0.57 0.25 0.26
P-value 0.0008 0.005 0.02
Primary variables Vit B6***
Vit C***
N-Methy-nicotinamide***
Vit K**
Vit B2*
Lipoic Acid *
Kryptopyroles*
Vit C **
N-methyl-nicotinamide *
Vit C ***
Vit B6 **
N-methyl-nicotinamide **
Vit K *
Minerals
Adjusted R2 0.38 0.22 0.27
P-value 0.0007 0.007 0.003
Primary variables Calcium (RBC) ***
Iron (RBC) **
Zinc (WB) **
Selenium (WB) **
Manganese (RBC) *
Copper (WB) *
Lithium (WB) *
Zinc (RBC) *
Iron (RBC) ***
Calcium (RBC) **
Potassium (RBC) *
Zinc (WB) *
Iron (RBC) ***
Calcium (RBC) **
Zinc (RBC) **
Potassium (RBC) **
Vanadium (RBC) *
* variable has a significance of p < 0.05
** variable has a significance of p < 0.01
*** variable has a significance of p < 0.001
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biomarker, the Overall analysis is best interpreted as
demonstrating that variations in the severity of autism
are strongly associated with the nutritional and meta-
bolic biomarkers investigated in this study. Of course,
other factors not addressed in this study also contri-
bute to the severity of autism, and all of these factors
are worthy of further research.
These significant associations may offer clues to the
etiology of autism. Vitamins, minerals, and essential
amino acids are, by definition, essential for human life,
so low levels of those critical nutrients will impair
metabolic pathways and may contribute to the devel-
opmental delays which occur in autism. We hypothe-
size that the nutritional and metabolic problems
reported in this study may be associated with the
etiology of autism. We also hypothesize that correction
of these problems may help reduce some of the symp-
toms and co-morbidities of autism, although much
more research is needed to investigate these
hypotheses.
Comparison with other studies
There are two other general studies that are also inter-
esting to compare with our results. One study [18]
found inadequate intake of folic acid, vitamin B6, cal-
cium, vitamin A, vitamin C, and zinc in most children
with autism in China. However, they only assessed diet-
ary intake, and compared dietary intake based on estab-
lished literature values (no control group); they did not
measure blood levels.
Table 14 Regression analysis of autism severity and plasma amino acids
PDD-BI ATEC SAS
Primary Plasma Amino Acids (20)
Adjusted R2 0.39 0.22 0.24
P-value 0.001 0.01 0.007
Primary variables Proline **
Serine **
Leucine**
Valine *
Taurine *
Asparagine **
Tryptophan *
Glutamic Acid *
Glutamine *
Phenylalanine *
Serine **
Asparagine *
Proline *
Other Amino Acids
Adjusted R2 0.23 0.26 0.18
P-value 0.008 0.005 0.04
Primary variables Beta-amino-isobutyrate **
Ethanolamine *
Sarcosine *
Ethanolamine **
Sarcosine **
Beta-amino-isobutyrate **
1-methyl-histidine *
Ethanolamine *
* variable has a significance of p < 0.05
** variable has a significance of p < 0.01
*** variable has a significance of p < 0.001
Table 15 Regression Analysis for Autism Severity vs. Sulfation/Methylation/Glutathione/Oxidative Stress, and vs. ATP/
NADH/NADPH/CoQ10
PDD-BI ATEC SAS
Sulfation, Methylation, Glutathione, Oxidative Stress
Adjusted R2 0.20 0.15 0.24
P-value 0.005 0.03 0.002
Primary variables Free Sulfate **
SAM *
Oxidized Glut. *
Free Sulfate **
SAM *
Oxidized Glut. *
Free Sulfate **
Oxidized Glutat. *
Adenosine *
ATP, NADH, NADPH, CoQ10
Adjusted R2 0.13
P-value n.s. 0.01 n.s.
Primary variables NADH **
ATP *
* variable has a significance of p < 0.05
** variable has a significance of p < 0.01
*** variable has a significance of p < 0.001
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It is also interesting to compare our results with a
study by Mehl-Madrona et al 2010 [79]. The present
results suggest that micronutrient therapy with vita-
mins and minerals would be beneficial, and that is
consistent with their study, which found that micro-
nutrient supplementation was comparable with phar-
maceuticals in terms of improvements in the
Childhood Autism Rating Scale, and resulted in better
improvements on the Aberrant Behavior Checklist (p
< 0.0001), Clinical Global Impressions (p = 0.003), and
Self-Injurious Behavior (p = 0.005). Similarly, a small
randomized, double-blind, placebo-controlled study of
a multi-vitamin/mineral supplement found that it was
beneficial to children with autism, primarily in redu-
cing gastrointestinal problems and sleep problems
[45].
Limitations of this study
1) The diagnosis of an autism spectrum disorder by
a qualified medical professional was verified in writ-
ing, but there no additional verification. Similarly,
for the neurotypical children, no additional verifica-
tion was made beyond the parental report.
2) The sample size of 55 children with ASD and 44
neurotypical children was large enough to observe
many significant differences between the two groups,
but some differences were only marginally or possi-
bly significant - another study, preferably with larger
number of participants, is needed to verify some of
the observations.
3) Although several functional tests of need for vita-
mins were conducted, several more could have been
added, but there were limitations on the total
amount of tests that could be done with the blood
that was drawn.
4) Medication effects: 45% of the children with aut-
ism were taking one or more medications (see Table
1), but those medications appear to have had little
effect on the study results (see Medication Effects in
the Results section).
5) Dietary effects: 16% of the children with autism
were on special diets (see Table 1), which might
have had some effect on the results.
6) All the study participants were from Arizona, so
the results for this region may be somewhat different
from other parts of the US or the world.
Conclusions
Many significant differences (p < 0.001) were observed
in the autism group compared to the neurotypical
group, including low levels of biotin, plasma glutathione,
RBC SAM, plasma uridine, plasma ATP, RBC NADH,
RBC NADPH, plasma sulfate (free and total), and
plasma tryptophan; and high levels of oxidative stress
markers and plasma glutamate. Decreased ATP may be
a contributing factor to decreased sulfate and decreased
SAM/methylation. Decreased NADPH may be a cause
of the increased oxidation of glutathione. This study
replicated previous findings of very low lithium in chil-
dren with ASD, but the p-value was only 0.006 (possibly
significant). There were also many marginal differences,
and many possible differences, but a larger study is
needed to confirm the validity of those observations.
Overall, it appears that children with autism do have
many abnormalities in their nutritional and metabolic
status. The underlying causal relationships of these
abnormalities are not yet well understood. An important
issue in the clinical care of ASD children is that most
vitamins, minerals, and plasma amino acids were within
the reference range, but other biomarkers (oxidative
stress, methylation, sulfation) were very abnormal, sug-
gesting that those other biomarkers can be important
guides for treatment.
The regression analysis found that some vitamins,
minerals, amino acids, and (to a lesser extent) other bio-
markers are significantly associated with variations in
Table 16 Regression analysis of autism severity vs. highly significant biomarkers (defined as p < 0.01, in a previous
regression analysis)
PDD-BI ATEC SAS
Significant Biomarkers
Adjusted R2 0.56 0.24 0.42
P-value 0.000003 0.002 0.0002
Primary variables Iron (RBC) ***
Methylmalonic Acid **
Glutamate **
Proline **
Serine
Sarcosine *
Ethanolamine *
Beta-amino-isobutyrate *
Free Sulfate *
Potassium (RBC) **
Calcium (RBC) **
N-Methyl-nicotinamide **
Serine **
Phenylalanine **
Alanine *
* variable has a significance of p < 0.05
** variable has a significance of p < 0.01
*** variable has a significance of p < 0.001
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the severity of autism, with vitamins being especially
important.
We hypothesize that support for these nutritional and
metabolic problems by increasing nutrient intake may
reduce the symptoms and co-morbidities that are asso-
ciated with autism. These nutritional and metabolic dys-
functions may be related to the etiology of autism.
Certainly much more research is needed to investigate
these hypotheses.
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